



## Veradermics CEO Reid Waldman is selected as a Forbes 30 Under 30 for 2024

November 29, 2024

NEW HAVEN, Conn., Nov. 29, 2023 /PRNewswire-PRWeb/ — Veradermics Inc., a clinical-stage medical dermatology company developing new therapeutics for a range of skin and hair loss conditions, today announced that Co-Founder and CEO, Reid Waldman, has been included in the 2024 Forbes “30 Under 30” Healthcare| New Window list, recognizing leading scientists and entrepreneurs developing innovative solutions that address some of healthcare’s biggest challenges.

Under Waldman’s leadership, Veradermics has raised nearly \$40 million from leading biotechnology investors since its founding in 2019 while developing a pipeline of five first-in-class product candidates targeting highly prevalent immunologic and dermatologic conditions. Two products of which Waldman is an inventor, including an immune stimulatory microarray for warts and a non-hormonal oral therapeutic for androgenetic alopecia, are currently in clinical trials. In a significant milestone, the company recently announced the dosing of the first patient in a clinical trial for its non-hormonal oral therapeutic for pattern hair loss.

“Inclusion in the Forbes “30 Under 30” list is not only a great honor for me on a personal level, but also a tremendous validation of the work we have done at Veradermics to advance the development of new dermatological therapeutics,” said Waldman. “With two of our products currently in trials and more in the pipeline, I remain excited to continue leading Veradermics forward as we strive to address common therapeutic challenges like warts, hair loss, and a variety of skin conditions.”

With more than 100 publications, presentations, and peer-reviewed works to his credit, Waldman is an award-winning researcher and one of the most cited physicians in the U.S., according to Doximity. A graduate of the prestigious 6-Year Accelerated BA/MD Program at the University of Missouri-Kansas City, he completed his Medicine Internship at Cedars-Sinai Medical Center in Los Angeles and his Dermatology Residency at the University of Connecticut. Already in Waldman’s brief career, he has been awarded the Excellence in Patient Care Award from the American Academy of Dermatology, the Resident of the Year Award from DermMentors, and the Resident Research Award from the University of Connecticut.

In addition to the two therapeutics currently in trials for warts and pattern hair loss, Veradermics pipeline also includes candidates targeting alopecia areata, atopic dermatitis, and molluscum contagiosum. The company expects to advance these additional product candidates into the clinic in 2024.

In addition to the above linked article, you may watch his video interview here: <https://www.forbes.com/video/6341124029112/this-doctor-wants-to-discover-the-next-breakthrough-drugs-in-dermatology/?sh=423e769c2cec> | New Window

About VeraDermics Inc.

VeraDermics Inc. is a dermatology-focused pharmaceutical company with a pipeline of patient-friendly therapeutics aimed at helping individuals affected by skin diseases. VeraDermics portfolio includes therapeutics addressing common warts, genital warts, alopecia areata, molluscum contagiosum, and beyond .